Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
Recruiting
Phase 1
Interventional Study
ALS (Amyotrophic Lateral Sclerosis)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 15 (estimated)
- Sponsor
- Celosia Therapeutics Pty Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of ALS in accordance with the revised El Escorial criteria and TRICALS risk score
* An overall disease duration of ≤ 2 years after the participant's first symptoms
* No or low circulating anti-AAV9 antibodies (titre ≤ 1:50
* Stable dosing with a standard of care ALS …
Contacts
No contact information available.